

RESEARCH

Open Access

Pathologic response with neoadjuvant chemotherapy and stereotactic body radiotherapy for borderline resectable and locally-advanced pancreatic cancer

Malolan S Rajagopalan¹, Dwight E Heron¹, Rodney E Wegner^{1,7}, Herbert J Zeh², Nathan Bahary³, Alyssa M Krasinskas⁴, Barry Lembersky³, Randall Brand⁵, A James Moser⁶, Annette E Quinn¹ and Steven A Burton^{1*}

Abstract

Background: Neoadjuvant stereotactic body radiotherapy (SBRT) has potential applicability in the management of borderline resectable and locally-advanced pancreatic adenocarcinoma. In this series, we report the pathologic outcomes in the subset of patients who underwent surgery after neoadjuvant SBRT.

Methods: Patients with borderline resectable or locally-advanced pancreatic adenocarcinoma who were treated with SBRT followed by resection were included. Chemotherapy was to the discretion of the medical oncologist and preceded SBRT for most patients.

Results: Twelve patients met inclusion criteria. Most (92%) received neoadjuvant chemotherapy, and gemcitabine/capecitabine was most frequently utilized (n = 7). Most were treated with fractionated SBRT to 36 Gy/3 fractions (n = 7) and the remainder with single fraction to 24 Gy (n = 5). No grade 3+ acute toxicities attributable to SBRT were found. Two patients developed post-surgical vascular complications and one died secondary to this. The mean time to surgery after SBRT was 3.3 months. An R0 resection was performed in 92% of patients (n = 11/12). In 25% (n = 3/12) of patients, a complete pathologic response was achieved, and an additional 16.7% (n = 2/12) demonstrated <10% viable tumor cells. Kaplan-Meier estimated median progression free survival is 27.4 months. Overall survival is 92%, 64% and 51% at 1-, 2-, and 3-years.

Conclusions: This study reports the pathologic response in patients treated with neoadjuvant chemotherapy and SBRT for borderline resectable and locally-advanced pancreatic cancer. In our experience, 92% achieved an R0 resection and 41.7% of patients demonstrated either complete or extensive pathologic response to treatment. The results of a phase II study of this novel approach will be forthcoming.

Keywords: Pancreatic cancer, Stereotactic body radiotherapy, SBRT, Neoadjuvant, Pathologic response

Background

Pancreatic cancer is the fourth leading cause of death from cancer in both men and women in the United States [1]. It is a highly aggressive entity with approximately 40% presenting as locally-advanced but unresectable disease and an additional 40% presenting with metastatic disease [2]. Despite intensive efforts with chemotherapy and radiation

therapy, surgical resection remains the only treatment option associated with long-term survival [3].

Chemotherapy and radiation therapy have been explored in the adjuvant setting. The GITSG trial was the only major clinical trial to demonstrate a survival benefit for adjuvant chemoradiation [4]. However, this study is routinely criticized for its small size, antiquated techniques and split-course radiation delivery. Furthermore, when attempted to be replicated by EORTC 40891, no benefit to adjuvant chemoradiation was demonstrated. Based upon this study and ESPAC-1, which does have a

* Correspondence: burtons@upmc.edu

¹Department of Radiation Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA

Full list of author information is available at the end of the article

number of flaws with design but found a deleterious effect of adjuvant chemoradiation, the use of adjuvant radiation has fallen out of favor in Europe and is controversial in North America [5,6]. Meanwhile, a number of studies including CONKO-001 and RTOG 9704 began to shed light that gemcitabine-based adjuvant chemotherapy may be more efficacious than previous regimens [7,8]. However, it must be noted that the recent update to ESPAC-3 found that adjuvant gemcitabine may be equivalent to adjuvant 5FU [9].

Neoadjuvant therapy has a number of potential benefits compared to adjuvant therapy. It may, in theory, eradicate micrometastatic disease while potentially downsizing the primary lesion to facilitate a margin negative (R0) resection. Many patients may never recover sufficiently to tolerate adjuvant therapy. Finally, patients can be selected for surgery and those who develop metastatic disease during the course of neoadjuvant therapy can be spared the morbidity and mortality risks associated with a pancreaticoduodenectomy. Neoadjuvant therapy was studied at MD Anderson Cancer Center in a retrospective series of over 300 patients. This series lent evidence that induction chemotherapy followed by concurrent chemo-radiation for unresectable cancer improved progression-free survival and median survival when compared to patients who underwent chemoradiation alone [10].

Stereotactic Body Radiotherapy (SBRT) is particularly promising for pancreatic cancer. SBRT enables the delivery of high doses to a small target in few fractions. By completing radiotherapy in the span of one or two weeks, the patient is potentially able to benefit from full doses of chemotherapy without interruption, less toxicity, and the ability to proceed to surgery faster. In this study, we retrospectively analyzed patients with locally advanced or borderline resectable pancreatic cancer who underwent neoadjuvant therapy with SBRT and completed surgical resection.

Methods

Patient population

Patients with biopsy-proven borderline resectable or locally-advanced pancreatic adenocarcinoma who were treated with neoadjuvant SBRT from 2008–2011 and completed surgical resection were included in this retrospective analysis. Definitions for borderline resectability and locally advanced disease were based on radiographic criteria defined by Varadhachary [11]. All patients were seen, evaluated, and followed by a pancreatico-biliary surgeon, medical oncologist and radiation oncologist in the Pancreas Multidisciplinary Clinic at the University of Pittsburgh Cancer Institute. This study was conducted under a formal Institutional Review Board approved protocol.

Chemotherapy

Most patients in this series received neoadjuvant chemotherapy. The choice of chemotherapy was to the discretion of the medical oncologist. Chemotherapy preceded SBRT whenever possible.

Radiation therapy

For stereotactic localization, fiducial markers were required prior to SBRT. Two to three fiducial markers were placed in or around the tumor. All patients underwent a 4D-CT treatment simulation with a custom-made relocatable Alpha Cradle® immobilization system (Smithers Medical Products, North Canton, OH). Target and critical structures (liver, small bowel, stomach, kidneys, and spinal cord) were contoured. The GTV was defined as the tumor visible on the CT scan, and in those with N1 disease, the nodes were not included in the target. The GTV was expanded by 2 mm to form the PTV.

The radiosurgical plan was devised to typically deliver a dose of 24 Gy in a single fraction or 36 Gy in 3 fractions. Patients treated during or before 2010 were treated with a single fraction. The multidisciplinary group chose to fractionate SBRT starting in 2011 to reduce the potential for toxicity. Recommended normal tissue constraints guidelines for three fractions were as follows: spinal cord <18 Gy, stomach <30 Gy, small bowel <25 Gy, liver 15 Gy to <700 cm³, kidney 15 Gy to <1/3 total volume. For single fraction treatment, the small bowel maximum point dose was 18.5 Gy. Plans were devised such that the prescription dose was the isodose line encompassing >95% of the PTV. No more than 20% of the PTV was to receive a dose >110% of the prescription dose. No more than 2% of the PTV was to receive <93% of the prescription dose. Patients were treated on any of three radiosurgical platforms including the Accuray CyberKnife® (Accuray Inc., Sunnyvale, CA) or Varian Trilogy® or TrueBeam® (Varian Medical Systems Inc., Palo Alto, CA).

All patients underwent motion-compensated treatment when required as determined by motion of the target. On the CyberKnife® platform, the Synchrony™ respiratory tracking system was utilized. For those treated on Trilogy® or TrueBeam®, the Real-time Position Management™ Respiratory Gating System (Varian Medical Systems, Inc. Palo Alto, CA) was utilized when required.

Surgery

Follow-up CT imaging was obtained in all patients 10–12 weeks after the completion of SBRT as was the standard protocol at our institution. If there was no evidence of distant metastasis and the malignancy appeared technically resectable, surgical exploration and curative resection was recommended. Surgery was performed by

experienced pancreatico-biliary surgeons. Patients underwent either classical pancreaticoduodenectomy or pylorus preserving pancreaticoduodenectomy for head tumors and distal pancreatectomy for body/tail lesions. When there was involvement of the celiac or hepatic artery, an Appleby procedure may have been performed. When required, vein reconstruction was also performed.

Pathology

All surgical pathology specimens were analyzed at the same lab in the University of Pittsburgh Cancer Institute. Negative margins were scored if there was at least a 1 mm margin of benign tissue. All pathologic specimens were re-reviewed and scored by an expert pathologist (AK). Pathologic response after neoadjuvant therapy was scored using the Evans' criteria as detailed in Table 1 [12].

Statistical methods

All figures are reported as mean ± standard deviation except when otherwise indicated. Kaplan-Meier survival analysis was used to estimate overall survival (OS) and progression free survival (PFS). Survival rates were calculated from the date of biopsy. Acute toxicities were defined as those occurring within 90 days of SBRT and late toxicities were defined as those occurring thereafter. SPSS® software version 18.0 (IBM Corp., Armonk, NY) was used for statistical analysis.

Results

Patient characteristics

One-hundred and five patients were treated at our institution with SBRT for pancreatic cancer for primary or definitive intent. Of these, twelve patients underwent surgical resection after SBRT and thus met criteria for inclusion in this retrospective series. The median age was 68 (range: 82–41 years) and 41.7% were male. All patients were considered to have locally advanced (n = 5/12) or borderline resectable (n = 7/12) disease as determined by experienced pancreatic surgeons. Patients were evenly divided between T3 (50%) and T4 (50%) stage. The majority of patients were N0, but 41.7% had N1 disease.

Table 1 Evans' criteria for pathologic response following neoadjuvant therapy

Grade	Tumor regression
I	<10% to no tumor cells destroyed
II	IIa: 10-50% of tumor cells destroyed
	IIb: 50-90% of tumor cells destroyed
III	>90% of tumor cells destroyed
IV	IIIM: sizable pools of cellular mucin
	No viable tumor cells
	IVM: Acellular pools of mucin

Chemotherapy


Most patients (91.7%) had neoadjuvant chemotherapy following diagnosis and preceding SBRT. One patient did not have neoadjuvant chemotherapy due to recent bone marrow transplant for multiple myeloma. In this case, single-agent gemcitabine was deferred to the adjuvant setting. Among those who received neoadjuvant chemotherapy, it was gemcitabine-based in the vast majority (90.9%) and most received gemcitabine /capecitabine (n = 7/11). Other neoadjuvant chemotherapy regimens included gemcitabine/erlotinib, gemcitabine alone, FOLFIRINOX and gemcitabine/Abaxane® followed by FOLFIRINOX. Following surgery, the majority of patients (75%) did receive additional chemotherapy in the adjuvant setting.

Stereotactic body radiotherapy

SBRT was delivered at a single site by experienced radiation oncologists. Treatment was delivered on either the CyberKnife® platform for 33% of the patients and the remaining patients were treated on the Varian Trilogy™ or TrueBeam™ platforms. Patients treated from 2008 – 2010 received a single fraction dose of 24 Gy (n = 5/12) while those treated in 2011 typically received a hypofractionated course of 36 Gy in 3 fractions (n = 6/12) and one received 30 Gy in 3 fractions (Figure 1). The mean target volume was 16.6 cm³ (range: 5.1 – 44.6 cm³). Intensity modulated radiosurgery plans typically involved 11–13 fields while those on the CyberKnife® platform utilized 150–170 beams. Maximum spinal cord doses were 1.56 Gy (range: 1.0 – 1.8 Gy) for single fraction plans and 6.6 Gy (range: 1.3 – 10.2 Gy) for hypofractionated plans. Maximum bowel doses were 13.7 Gy (range: 11.3 – 16.1 Gy) and 21.6 Gy (16.8 – 25.1 Gy) for single and multi-fraction plans respectively. There were no acute grade 3 or higher toxicities directly attributable to SBRT.

Surgery

The mean time to surgery following SBRT was 3.3 months (range: 1.5 – 6.6 months). Vein reconstruction was performed in 25% of cases. Postoperative complications included pseudoaneurysm, bradycardia, infection and bleeding. There was one patient who suffered both post-operative infection and bleeding in the postoperative period and eventually succumbed to this. This was felt to be a technical complication related to the surgery and narrow vasculature and not related to SBRT. However, two other patients developed pseudoaneurysms which are thought to be related to SBRT. One patient, who underwent surgery 6.6 months following SBRT, developed a pseudoaneurysm of the gastroduodenal artery in the absence of a pancreatic leak and required coiling. She recovered well from the procedure. Another patient, who underwent surgery 4.5 months after SBRT, developed a pseudoaneurysm of the splenic



artery stump with gastrointestinal bleeding. This patient required multiple procedures approximately 6.5 months following surgery, and eventually died of complications related to this. After multidisciplinary review, the group believes that these two vascular complications are related to a long interval between SBRT and definitive surgical management.

Pathology

Final pathology revealed that an R0 resection with at least a 1 mm margin was achieved in the vast majority of patients (91.7%). There was only one patient who had a positive margin and this patient had borderline resectable disease at diagnosis. All patients who underwent a vein reconstruction achieved an R0 resection.

Three patients (25%) achieved a complete pathologic response (pCR) to neoadjuvant therapy (Figure 2). These patients were treated with SBRT to 36 Gy in three fractions. Two patients (16.7%) had >90% of tumor cells destroyed and an additional two (16.7%) had > 50% tumor cell destruction when scored by Evans' criteria (Table 2). Thus 41.7% of patients had at least 90% tumor cell destruction in response to neoadjuvant therapy and a total of 58.3% had at least 50% tumor cell destruction.

Survival

Survival data is available with a median follow-up of 16.6 months (range: 10.5 – 54.5 months). Kaplan-Meier estimated 1-, 2-, and 3-year OS is 92%, 64% and 51% respectively (Figure 3). Kaplan-Meier estimated median survival is 47.2 months and median PFS is 27.4 months. Due to the small numbers in this study, subset analyses correlating time to surgery and pathologic response and pCR or R0 resection to outcome were not significant.

Discussion

Herein we present pathologic outcomes in a series of patients with locally advanced and borderline resectable pancreatic cancer who underwent neoadjuvant SBRT. We found that in this cohort, the pCR rate was 25% and an additional 16.7% had an extensive response to therapy with >90% tumor cell destruction. The estimated 1-, 2-, and 3-year OS is 92%, 64% and 51%.

Most of the published studies analyzing SBRT have been performed in locally advanced, unresectable disease. Memorial Sloan Kettering has reported outcomes for patients treated in a phase II study with sequential gemcitabine and SBRT approach (with chemotherapy preceding and following SBRT) [13]. SBRT was delivered as a single fraction of 25 Gy using the Varian Trilogy®




Figure 2 The same patient had a complete pathologic response following neoadjuvant chemotherapy and SBRT. Panel **A** is from the pre-treatment fine needle aspiration and shows adenocarcinoma. Panel **B** demonstrates extensive fibrosis in the surgical resection post-treatment with no evidence of invasive adenocarcinoma. The small nests of cells that are present within the dense fibrosis are all islets (*=cystically dilated duct lined by PanIN-3). Inset shows higher magnification of the boxed area, including one islet and PanIN-3.

platform. Toxicities reported included duodenal perforation requiring surgery (5%). Median survival was 11.8 months and 1-year survival was 50%. The same group has previously reported a similar series of patients receiving gemcitabine and a single fraction of 25 Gy of SBRT delivered on the CyberKnife® platform [14]. Similar outcomes were reported with 11.4 months median survival and 1-year survival of 50% was noted. Acute toxicities included gastric outlet obstruction (6.3%). Late gastrointestinal toxicities included duodenal perforation and stricture (12.5%). Our institution has also reported a series of SBRT for locally advanced, unresectable disease

[15]. The vast majority of patients were treated with a single fraction of 24 Gy. The rate of acute grade 3 or higher toxicities was 1.4%. Median survival in this series was 10.3 months and 1-year OS was 41%. A Harvard series assessing gemcitabine and fractionated SBRT (24 – 36 Gy) in the same population revealed a 14% grade 3 toxicity rate with MS of 14.3 months [16]. Finally, Stanford has reported on 77 patients with unresectable disease receiving single fraction of 25 Gy and demonstrated a 1-year rate of freedom from local progression of 84%, 1-year PFS of 9%, and 1-year OS from SBRT 21%. They report a 9% late grade 3 or higher toxicity [17].


Table 2 Pathologic response following neoadjuvant therapy

	Neoadjuvant chemotherapy	Neoadjuvant SBRT (dose / fractions)	Pathologic response (Evans' criteria)
01	Gem./Cape.	36 Gy / 3	IV
02	Gem./Cape.	36 Gy / 3	IV
03	FOLFIRINOX, Gem./Abraxane	36 Gy / 3	IV
04	Gem./Erlotinib	24 Gy / 1	III
05	Gem./Cape.	24 Gy / 1	III
06	Gem.	24 Gy / 1	IIb
07	FOLFIRINOX	36 Gy / 3	IIb
08	N/A	36 Gy / 3	IIa
09	Gem./Cape.	36 Gy / 3	IIa
10	Gem./Cape.	24 Gy / 1	IIa
11	Gem./Cape.	24 Gy / 1	IIa
12	Gem./Cape.	30 Gy / 3	IIa

25% of patients achieved a complete pathologic (pCR) response to neoadjuvant therapy (Evans' grade: IV), and an additional 16.7% of patients had >90% tumor cell destruction (Evans' grade: III). In total, 58.3% of patients had at least 50% of tumor cell destruction (Evans' Grade: IIb - IV). For those achieving pCR, SBRT dose was 36 Gy in 3 fractions and neoadjuvant chemotherapy was gemcitabine-based. [Abbreviations: Gem Gemcitabine, Cape Capecitabine].

Toxicity with pancreatic SBRT is a particular concern and has come under scrutiny. The Danish group has reported on a phase II study of SBRT for locally advanced pancreatic cancer in which a central dose of 45 Gy in three fractions was delivered [18]. They found that there was a significant deterioration in performance status, pain and nausea associated with SBRT within 2 weeks, but most improved by 3 months. They found that 18% (n = 4/22) suffered severe gastrointestinal ulceration or mucositis and one had perforation of the stomach. The

Mayo Clinic undertook a dosimetric analysis of 47 patients undergoing abdominal SBRT to targets in proximity to hollow viscous organs [19]. A variety of dose and fractionations were used, but the most common was 50 Gy/5 fractions. There were no acute grade 3 or higher toxicities. Five late gastrointestinal toxicities were found, but no dose correlation could be ascertained. This report, taken in conjunction with the number of other reports detailing pancreatic SBRT, demonstrates the technique is feasible and can be performed with an



acceptable toxicity profile. Acute toxicities are infrequent and in this report no acute grade 3 or higher toxicities were seen. It is hypothesized that the late gastrointestinal toxicity rate attributable to SBRT may be less frequent in our approach since the distal stomach and duodenum, which can stricture, ulcerate or perforate, is resected shortly after SBRT. There were two patients who developed pseudoaneurysm in the post-operative period in the absence of pancreatic leak. Thus we suspect this is related to ischemic injury secondary to SBRT. In both these patients, the interval from SBRT to surgery was greater than 4 months. We now believe that a shorter interval may reduce the potential for toxicity. We have since modified our protocol to obtain follow-up imaging 4 weeks following SBRT with the goal of performing surgery with a shorter interval from SBRT.

In the preoperative setting, two reports describe patients treated with SBRT who underwent resection. An Italian group studied patients with initially unresectable pancreatic cancer who underwent gemcitabine followed by SBRT and resection when feasible. Of the 23 patients who were enrolled on protocol, only two underwent resection. Both had an R0 resection but both had positive peri-pancreatic lymph nodes. One was found to a pCR in the primary site and the other had a partial response. Moffitt has reported on a large series of patients undergoing induction chemotherapy and SBRT for locally advanced and borderline resectable disease [20]. Of those that completed surgery, 97% had an R0 resection and the pCR rate was 9.4%.

There are a number of studies reporting pathologic outcomes following neoadjuvant chemotherapy with or without conventionally fractionated radiation therapy. A French group explored perioperative chemo-radiation and found a pCR rate of 7.5% (n = 3/40) [21]. MD Anderson Cancer Center has reported a phase II approach with neoadjuvant chemotherapy and radiation therapy and found a 2.7% pCR rate [22]. In a review of the experience at MD Anderson from 1995 – 2010, only 2.5% of patients who underwent neoadjuvant therapy and pancreatotomy achieved pCR. The authors concluded that, while rare, pCR was associated with extended survival [23].

There are limitations with our study as there are with all retrospective reports. Of the 105 patients treated with SBRT, only the twelve who completed both neoadjuvant therapy and surgery were included in the study and for survival analysis. Furthermore, the neoadjuvant approach, by design, selects for patients who do not develop distant metastases or extensive local progression that preclude use of SBRT. Thus, survival estimates reported in this series are expected to be higher than other reports. Finally, since most patients received neoadjuvant chemotherapy and SBRT, it is unknown if one of these modalities was the primary effector of the pathologic response.

Despite these limitations, however, this approach and these results are certainly promising. We believe an aggressive, tri-modality approach provides patients the greatest chance for a durable response and potential cure. Surgery has always remained the mainstay and those who are able to have it performed certainly benefit [3]. Chemotherapy has also proven benefit in a number of trials and is also an integral component of treatment. The role for long course, external beam radiation therapy in pancreatic cancer, however, remains nebulous. This approach allows full, systemic doses of chemotherapy to be delivered without interruption and allows the expeditious delivery of high dose radiation therapy before definitive surgical management.

Conclusions

In summary, we report our experience in a subset of patients with locally advanced and borderline resectable pancreatic cancer who were treated with neoadjuvant chemotherapy and SBRT followed by resection. We found that this approach is safe and is tolerated well. In our experience, 92% achieved an R0 resection and 41.7% of patients demonstrated either complete or extensive pathologic response to treatment. This is a promising area for further exploration in this disease site, and we currently have an ongoing phase II trial at our institution exploring this approach.

Competing interests

The authors have no financial or personal relationships with other people or organizations that could inappropriately influence this work.

Authors' contribution

MSR and AMK were responsible for data collection. MSR and AMK were responsible for data analysis. MSR, DEH, REW, HJZ, NB, RB, AJM, AEQ, and SAB were responsible for concept design. MSR, DEH, REW, HJZ, NB, AMK, BL, RB, AJM, and SAB authors were responsible for manuscript writing and editing. All authors read and approved the final manuscript.

Author details

¹Department of Radiation Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA. ²Department of Surgical Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA. ³Department of Medical Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA. ⁴Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA. ⁵Department of Gastroenterology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA. ⁶Department of Surgery, Beth Israel Deaconess Medical Center, Boston, MA, USA. ⁷Current address: Delta Medix Center for Comprehensive Cancer Care, Scranton, PA, USA.

Received: 15 July 2013 Accepted: 27 October 2013

Published: 31 October 2013

References

1. Siegel R, Naishadham D, Jemal A: **Cancer statistics, 2012.** *CA Cancer J Clin* 2012, **62**:10–29.
2. Neoptolemos JP, Cunningham D, Friess H, Bassi C, Stocken DD, Tait DM, Dunn JA, Dervenis C, Lacaine F, Hickey H, et al: **Adjuvant therapy in pancreatic cancer: historical and current perspectives.** *Ann Oncol* 2003, **14**:675–692.
3. Yeo CJ, Cameron JL, Lillemoe KD, Sitzmann JV, Hruban RH, Goodman SN, Dooley WC, Coleman J, Pitt HA: **Pancreaticoduodenectomy for cancer of**

- the head of the pancreas. 201 patients. *Ann Surg* 1995, **221**:721–731. discussion 731–723.
4. Kalsner MH, Ellenberg SS: **Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.** *Arch Surg* 1985, **120**:899–903.
 5. Smeenk HG, van Eijck CH, Hop WC, Erdmann J, Tran KC, Debois M, van Cutsem E, van Dekken H, Klinkenbijnl JH, Jeekel J: **Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation: long-term results of EORTC trial 40891.** *Ann Surg* 2007, **246**:734–740.
 6. Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, Beger H, Fernandez-Cruz L, Dervenis C, Lacaine F, et al: **A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.** *N Engl J Med* 2004, **350**:1200–1210.
 7. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, Schramm H, Fahike J, Zuelke C, Burkart C, et al: **Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.** *JAMA* 2007, **297**:267–277.
 8. Regine WF, Winter KA, Abrams R, Safran H, Hoffman JP, Kanski A, Benson AB, Macdonald JS, Rich TA, Willett CG: **Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial.** *Ann Surg Oncol* 2011, **18**:1319–1326.
 9. Neoptolemos J, Büchler M, Stocken DD, Ghaneh P, Smith D, Bassi C, Moore M, Cunningham D, Dervenis C, Goldstein D: **ESPAC-3(v2): A multicenter, international, open-label, randomized, controlled phase III trial of adjuvant 5-fluorouracil/folinic acid (5-FU/FA) versus gemcitabine (GEM) in patients with resected pancreatic ductal adenocarcinoma.** *J Clin Oncol* 2009, **27**, LBA4505.
 10. Krishnan S, Rana V, Janjan NA, Varadhachary GR, Abbruzzese JL, Das P, Delclos ME, Gould MS, Evans DB, Wolff RA, Crane CH: **Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy.** *Cancer* 2007, **110**:47–55.
 11. Varadhachary GR, Tamm EP, Abbruzzese JL, Xiong HQ, Crane CH, Wang H, Lee JE, Pisters PW, Evans DB, Wolff RA: **Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy.** *Ann Surg Oncol* 2006, **13**:1035–1046.
 12. Evans DB, Rich TA, Byrd DR, Cleary KR, Connelly JH, Levin B, Chamsangavej C, Fenoglio CJ, Ames FC: **Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas.** *Arch Surg* 1992, **127**:1335–1339.
 13. Schellenberg D, Kim J, Christman-Skieller C, Chun CL, Columbo LA, Ford JM, Fisher GA, Kunz PL, Van Dam J, Quon A, et al: **Single-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer.** *Int J Radiat Oncol Biol Phys* 2011, **81**:181–188.
 14. Schellenberg D, Goodman KA, Lee F, Chang S, Kuo T, Ford JM, Fisher GA, Quon A, Desser TS, Norton J, et al: **Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer.** *Int J Radiat Oncol Biol Phys* 2008, **72**:678–686.
 15. Rwigyema JC, Parikh SD, Heron DE, Howell M, Zeh H, Moser AJ, Bahary N, Quinn A, Burton SA: **Stereotactic body radiotherapy in the treatment of advanced adenocarcinoma of the pancreas.** *Am J Clin Oncol* 2011, **34**:63–69.
 16. Mahadevan A, Jain S, Goldstein M, Miaksd R, Pleskow D, Sawhney M, Brennan D, Callery M, Vollmer C: **Stereotactic body radiotherapy and gemcitabine for locally advanced pancreatic cancer.** *Int J Radiat Oncol Biol Phys* 2010, **78**:735–742.
 17. Chang DT, Schellenberg D, Shen J, Kim J, Goodman KA, Fisher GA, Ford JM, Desser T, Quon A, Koong AC: **Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas.** *Cancer* 2009, **115**:665–672.
 18. Hoyer M, Roed H, Sengelov L, Traberg A, Ohlhuis L, Pedersen J, Nellesmann H, Kiil Berthelsen A, Eberholst F, Engelholm SA, von der Maase H: **Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma.** *Radiother Oncol* 2005, **76**:48–53.
 19. Barney BM, Olivier KR, Macdonald OK, de Los Santos LE F, Miller RC, Haddock MG: **Clinical outcomes and dosimetric considerations using stereotactic body radiotherapy for abdominopelvic tumors.** *Am J Clin Oncol* 2012, **35**:537–542.
 20. Chuong MD, Springett GM, Freilich JM, Park CK, Weber JM, Mellon EA, Hodul PJ, Malafa MP, Meredith KL, Hoffe SE, Shridhar R: **Stereotactic Body Radiation Therapy for Locally Advanced and Borderline Resectable Pancreatic Cancer Is Effective and Well Tolerated.** *Int J Radiat Oncol Biol Phys* 2013, **86**:516–522.
 21. Moutardier V, Magnin V, Turrini O, Viret F, Hennekinne-Mucci S, Goncalves A, Pesenti C, Guirmand J, Lelong B, Giovannini M, et al: **Assessment of pathologic response after preoperative chemoradiotherapy and surgery in pancreatic adenocarcinoma.** *Int J Radiat Oncol Biol Phys* 2004, **60**:437–443.
 22. Evans DB, Varadhachary GR, Crane CH, Sun CC, Lee JE, Pisters PW, Vauthey JN, Wang H, Cleary KR, Staerke GA, et al: **Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head.** *J Clin Oncol* 2008, **26**:3496–3502.
 23. Zhao Q, Rashid A, Gong Y, Katz MH, Lee JE, Wolf R, Balachandran A, Varadhachary GR, Pisters PW, Wang H, et al: **Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with a better prognosis.** *Ann Diagn Pathol* 2012, **16**:29–37.

doi:10.1186/1748-717X-8-254

Cite this article as: Rajagopalan et al.: Pathologic response with neoadjuvant chemotherapy and stereotactic body radiotherapy for borderline resectable and locally-advanced pancreatic cancer. *Radiation Oncology* 2013 **8**:254.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

